Social media

Why are clinical trial start-up timelines getting longer despite digital innovation? ICON’s industry survey of 100+ sites and commentary from Brian Mallon, EVP Site & Patient Solutions, uncover the complexity, contract...

Why are clinical trial start-up timelines getting longer despite digital innovation? ICON’s industry survey of 100+ sites and commentary from Brian Mallon, EVP Site & Patient Solutions, uncover the complexity, contract...

Vaccine guidance for patients with rare autoimmune diseases can be challenging, given the low prevalence of some of these conditions and limited understanding of the impacts of vaccines in these patients. Discover how va...

Rare autoimmune diseases can leave patients particularly vulnerable to infection, but they often require unique considerations for vaccination. Learn what makes these cases so unique, and what to take into account when b...

China’s life‑sciences sector continues to advance rapidly, creating new opportunities for more efficient and globally competitive clinical development. In ICON’s latest blog, Yao Zhong outlines the key factors enabling i...

China’s life‑sciences sector continues to advance rapidly, creating new opportunities for more efficient and globally competitive clinical development. In ICON’s latest blog, Yao Zhong outlines the key factors enabling i...

Join ICON at #OCT Southeast on 10 March at 9:30am EST as Shelley McLendon, Senior Vice President, Program Management, shares a CRO perspective on the global biotech sector. She will discuss the landscape shaping biotec...

Human ADME studies are essential for understanding how investigational drugs are absorbed, distributed, metabolised and excreted. Yet traditional sampling—limited to plasma, urine and faeces- leaves a key blind spot: bil...

Human ADME studies are essential for understanding how investigational drugs are absorbed, distributed, metabolised and excreted. Yet traditional sampling—limited to plasma, urine and faeces- leaves a key blind spot: bil...

Non-invasive testing could transform the management of metabolic liver disease and help shape the future of MASH clinical development. This article in SelectScience® Science explores the evolving NIT landscape, emerging...

Non-invasive testing could transform the management of metabolic liver disease and help shape the future of MASH clinical development. This article in Select Science explores the evolving NIT landscape, emerging regulat...

On 15 April at 12:00 pm, join ICON’s Alan Baldridge at the GLP‑1‑Based Therapeutics Summit for his session, “Is there anything GLP‑1s can’t do? Unlocking the next generation of metabolic treatments.” He will offer a fo...